Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX®) and a tetanus monovalent vaccine in healthy adults: new considerations for the management of patients with tetanus-prone injuries.

Abstract:

UNLABELLED:In adults with a tetanus-prone injury, combined vaccines such as Tdap-IPV (REPEVAX®) can boost immunity against several diseases simultaneously. This Phase IIIb, parallel-group, open-label trial compared antibody responses to Tdap-IPV and tetanus monovalent vaccine (TMV; Vaccin Tétanique Pasteur® or Tetavax®) against tetanus toxoid 10 and 28 d post-vaccination. Between July and December 2009, four centers in France and five in Germany recruited healthy adults who had received a tetanus-containing vaccine 5-10 y previously. Participants were randomized 1:1 to receive at the first visit a single dose (0.5 mL) of Tdap-IPV or TMV, with follow-up visits at Day 10 and Day 28. OUTCOMES:per protocol (PP) population immunogenicity at Day 10 (primary) and at Day 28 (secondary); safety throughout the study. Of 456 adults randomized, 223 received Tdap-IPV and 233 received TMV (PP population: 183 and 199 participants, respectively). All participants receiving Tdap-IPV and 99.0% receiving TMV had an anti-tetanus antibody concentration ≥ 0.1 IU/mL, confirming non-inferiority of Tdap-IPV to TMV (95% confidence interval of the difference: -1.2, 3.6). Number of adverse events reported was comparable in each group. Injection-site reactions were reported by 76.6% participants receiving Tdap-IPV and 74.6% receiving TMV. Systemic events (e.g., malaise, myalgia and headache) were reported in 47.7% and 39.7% of the Tdap-IPV and the TMV groups, respectively. Tdap-IPV is effective and well-tolerated for use in the management of tetanus-prone injuries in emergency settings in persons for whom a booster against diphtheria, pertussis and poliomyelitis is also needed.

journal_name

Hum Vaccin Immunother

authors

Laurichesse H,Zimmermann U,Galtier F,Launay O,Duval X,Richard P,Sadorge C,Soubeyrand B

doi

10.4161/hv.22083

subject

Has Abstract

pub_date

2012-12-01 00:00:00

pages

1875-81

issue

12

eissn

2164-5515

issn

2164-554X

pii

22083

journal_volume

8

pub_type

杂志文章,多中心研究,随机对照试验
  • Completeness and timeliness of vaccination and determinants for low and late uptake among young children in eastern China.

    abstract:BACKGROUND:We studied completeness and timeliness of vaccination and determinants for low and delayed uptake in children born between 2008 and 2009 in Zhejiang province in eastern China. METHODS:We used data from a cross-sectional cluster survey conducted in 2011, which included 1146 children born from 1 Jan 2008 to 3...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.28054

    authors: Hu Y,Chen Y,Guo J,Tang X,Shen L

    更新日期:2014-01-01 00:00:00

  • High dose hepatitis B vaccine is not effective in patients using immunomodulatory drugs: a pilot study.

    abstract::In patients undergoing immunotherapy, the quality of the immune response is reduced, which may negatively affect the efficacy of vaccination. This study was conducted in order to evaluate the efficacy of the hepatitis B virus (HBV) vaccine in patients using immunomodulators. Seronegative patients for HBV who were usin...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1574151

    authors: Haykir Solay A,Eser F

    更新日期:2019-01-01 00:00:00

  • Maternal immunization. Clinical experiences, challenges, and opportunities in vaccine acceptance.

    abstract::Maternal immunization holds tremendous promise to improve maternal and neonatal health for a number of infectious conditions. The unique susceptibilities of pregnant women to infectious conditions, as well as the ability of maternally-derived antibody to offer vital neonatal protection (via placental transfer), togeth...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.4161/21645515.2014.970901

    authors: Moniz MH,Beigi RH

    更新日期:2014-01-01 00:00:00

  • Factors contributing to the immunogenicity of meningococcal conjugate vaccines.

    abstract::Various glycoprotein conjugate vaccines have been developed for the prevention of invasive meningococcal disease, having significant advantages over pure polysaccharide vaccines. One of the most important features of the conjugate vaccines is the induction of a T-cell dependent immune response, which enables both the ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2016.1153206

    authors: Bröker M,Berti F,Costantino P

    更新日期:2016-07-02 00:00:00

  • The cellular and humoral immune response to influenza vaccination is comparable in asthmatic and healthy subjects.

    abstract::Annual influenza vaccination is recommended as a preventive measure for all patients with asthma since asthma exacerbations in children and adults are associated to viral infections including influenza. There is concern about the adequate immune response in asthmatics with ICS treatment. The production of antibodies t...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1759995

    authors: Velasco-Medina AA,García-León ML,Velázquez-Sámano G,Wong-Chew RM

    更新日期:2020-05-21 00:00:00

  • Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets.

    abstract::Despite the impressive impact of vaccines on public health, the success of vaccines targeting many important pathogens and cancers has to date been limited. The burden of infectious diseases today is mainly caused by antigenically variable pathogens (AVPs), which escape immune responses induced by prior infection or v...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2016.1191718

    authors: Servín-Blanco R,Zamora-Alvarado R,Gevorkian G,Manoutcharian K

    更新日期:2016-10-02 00:00:00

  • The development of a recombinant hepatitis E vaccine HEV 239.

    abstract::Hepatitis E virus (HEV) infection is one of the main causes of acute hepatitis worldwide. A recombinant hepatitis E vaccine, HEV 239, has been licensed in China for immunizing adults of 16 y old and above. The vaccine antigen contains pORF2 aa 368 - 606 of the HEV genotype 1 expressed in E. coli. The quality of the va...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2015.1008870

    authors: Li SW,Zhao Q,Wu T,Chen S,Zhang J,Xia NS

    更新日期:2015-01-01 00:00:00

  • Production of inflammatory cytokines in response to diphtheria-pertussis-tetanus (DPT), haemophilus influenzae type b (Hib), and 7-valent pneumococcal (PCV7) vaccines.

    abstract::Haemophilus influenzae type b (Hib) and 7-valent pneumococcal (PCV7) vaccines both became recommended in Japan in 2010. In this study, cytokine production was investigated in peripheral blood mononuclear cells (PBMCs) cultures stimulated with diphtheria and tetanus toxoids combined with acellular pertussis vaccine (DP...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.27264

    authors: Kashiwagi Y,Miyata A,Kumagai T,Maehara K,Suzuki E,Nagai T,Ozaki T,Nishimura N,Okada K,Kawashima H,Nakayama T

    更新日期:2014-01-01 00:00:00

  • Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials.

    abstract::Dengue is prevalent in the Asia-Pacific region. Participants of two immunogenicity and safety phase II studies conducted in Singapore and Vietnam (NCT0088089 and NCT00875524, respectively) were followed for up to four years after third vaccine dose of a recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TD...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/21645515.2019.1578595

    authors: Tran NH,Chansinghakul D,Chong CY,Low CY,Shek LP,Luong CQ,Fargo C,Wartel TA,Sun S,Skipetrova A,Bouckenooghe A

    更新日期:2019-01-01 00:00:00

  • Ebola vaccines in clinical trial: The promising candidates.

    abstract::Ebola virus disease (EVD) has become a great threat to humans across the world in recent years. The 2014 Ebola epidemic in West Africa caused numerous deaths and attracted worldwide attentions. Since no specific drugs and treatments against EVD was available, vaccination was considered as the most promising and effect...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2016.1225637

    authors: Wang Y,Li J,Hu Y,Liang Q,Wei M,Zhu F

    更新日期:2017-01-02 00:00:00

  • Acute respiratory failure due to eosinophilic pneumonia following pneumococcal vaccination.

    abstract::A 68-year-old woman under maintenance hemodialysis was admitted to our hospital with fever and dyspnea that had developed two days after the second vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV23). She had received the first vaccination with PPV23 five years earlier without any complications....

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1631134

    authors: Kikuchi R,Iwai Y,Watanabe Y,Nakamura H,Aoshiba K

    更新日期:2019-01-01 00:00:00

  • Primary care-based surveillance to estimate the proportion of rotavirus gastroenteritis among Latvian children below 5 years of age with acute gastroenteritis.

    abstract::Background: Rotavirus (RV) is worldwide an important cause of acute gastroenteritis (AGE) in infants and young children. There is no specific treatment for AGE caused by RV (RVGE) but since 2006 two safe and effective vaccines have been available. RV vaccination was included in the national immunization program (NIP) ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2018.1534515

    authors: Tafalla M,Gardovska D,Gopala K,Kozlovska L

    更新日期:2019-01-01 00:00:00

  • Overexpressed oncogenic tumor-self antigens.

    abstract::Overexpressed tumor-self antigens represent the largest group of candidate vaccine targets. Those exhibiting a role in oncogenesis may be some of the least studied but perhaps most promising. This review considers this subset of self antigens by highlighting vaccine efforts for some of the better known members and foc...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.4161/hv.29475

    authors: Bright RK,Bright JD,Byrne JA

    更新日期:2014-01-01 00:00:00

  • Prevention of pertussis: An unresolved problem.

    abstract::Pertussis is a highly contagious respiratory disease caused by Bordetella pertussis. However, after the introduction of the whole-cell pertussis vaccine (wP), the annual incidence rates of the disease progressively declined. Despite this result, the inclusion of wP in the national immunization schedule of infants and ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2018.1480298

    authors: Esposito S,Principi N

    更新日期:2018-01-01 00:00:00

  • Mycobacterial Hsp65 antigen upregulates the cellular immune response of healthy individuals compared with tuberculosis patients.

    abstract::Previously we showed that 65-kDa Mycobacterium leprae heat shock protein (Hsp65) is a target for the development of a tuberculosis vaccine. Here we evaluated peripheral blood mononuclear cells (PBMC) from healthy individuals or tuberculosis patients stimulated with two forms of Hsp65 antigen, recombinant DNA that enco...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2016.1264547

    authors: Wowk PF,Franco LH,Fonseca DMD,Paula MO,Vianna ÉDSO,Wendling AP,Augusto VM,Elói-Santos SM,Teixeira-Carvalho A,Silva FDC,Vinhas SA,Martins-Filho OA,Palaci M,Silva CL,Bonato VLD

    更新日期:2017-05-04 00:00:00

  • Human papillomavirus vaccination uptake: a longitudinal study showing ethnic differences in the influence of the intention-to-vaccinate among parent-daughter dyads.

    abstract:INTRODUCTION:It is unclear what role daughters play in the decision-making process regarding HPV vaccination. Therefore, we explored the impact of HPV vaccination intention among parents and their 12-13 year-old daughters on HPV vaccination uptake. METHODS:In February 2014 parents/guardians and their 12-13 year-old da...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1808411

    authors: Jongen VW,van der Loeff MFS,Boyd A,Petrignani M,Prins M,van der Wal M,Nielen A,de Melker H,Paulussen TGWM,Alberts CJ

    更新日期:2020-09-23 00:00:00

  • Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine.

    abstract::A previous phase 3, randomized, multicenter study showed the immunogenicity of a primary vaccination of subjects aged 11 to 17 years with the quadrivalent meningococcal vaccine conjugated to tetanus toxoid (MenACWY-TT) or the quadrivalent meningococcal polysaccharide vaccine (MenACWY-PS). This extension study evaluate...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1744363

    authors: Quiambao B,Peyrani P,Li P,Cutler MW,Van Der Wielen M,Perez JL,Webber C

    更新日期:2020-06-02 00:00:00

  • A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.

    abstract::The present study evaluated the safety and immunogenicity of the 2013/2014 trivalent surface antigen inactivated subunit seasonal influenza virus vaccine Fluvirin® in healthy adults (18 - ≤ 60 years) and elderly (>60 years). The vaccine contained 15 µg haemagglutinin protein from each of influenza A/California/7/2009 ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2015.1064570

    authors: Roggelin L,Vinnemeier CD,Meyer S,Witte K,Marx L,Theeß W,Burchard GD,Rolling T,Cramer JP

    更新日期:2015-01-01 00:00:00

  • The clinical, immunological and microbiological impact of the 10-valent pneumococcal-Protein D conjugate vaccine in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: A multi-centre, double-blind,

    abstract::We aimed to determine the efficacy of the 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in children aged 18-months to <18-years with recurrent protracted bacterial bronchitis (rPBB), chronic suppurative lung disease (CSLD) or bronchiectasis. In a multi-centre, double-blind randomi...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2018.1488562

    authors: O'Grady KF,Chang AB,Cripps A,Mulholland EK,Smith-Vaughan H,Wood N,Danchin M,Thornton R,Wilson A,Torzillo PJ,Morris PM,Richmond P,Rablin S,Arnold D,Connor A,Goyal V,Stoney T,Perrett K,Grimwood K

    更新日期:2018-01-01 00:00:00

  • The burden of infant group B streptococcal infections in Ontario: Analysis of administrative data to estimate the potential benefits of new vaccines.

    abstract::Group B streptococcus (GBS) is a leading bacterial cause of neonatal sepsis and meningitis in many countries as well as an important cause of disease in pregnant women. Currently, serotype-specific conjugate vaccines are being developed. We conducted an epidemiological analysis of health administrative data to estimat...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2018.1511666

    authors: Hartley J,Li Y,Kunkel L,Crowcroft NS

    更新日期:2019-01-01 00:00:00

  • Influences on HPV vaccination across levels of the social ecological model: perspectives from state level stakeholders.

    abstract::Nationally, human papillomavirus (HPV) vaccination rates fall short of the Healthy People 2020 goal of 80% completion. Although strategies to increase these rates exist, low rates persist. We used concept mapping with state-level stakeholders to better understand barriers and facilitators to HPV vaccination. Concept m...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1839290

    authors: Ryan G,Avdic L,Daly E,Askelson N,Farris PE,Shannon J,McRee AL,Hanson J,Kenyon DB,Seegmiller L

    更新日期:2020-12-17 00:00:00

  • What is the cost of delivering routine vaccinations at GP practices in England? A comparative time-driven activity-based costing analysis.

    abstract::Background: The expansion of available vaccines in recent years has increased the overall costs of the vaccine program and put pressure on providers responsible for vaccination. In England in 2016-17, GP practices responsible for vaccinating their local population were paid £227 million. However, the costs to general ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1619403

    authors: Crocker-Buque T,Mohan K,Ramsay M,Edelstein M,Mounier-Jack S

    更新日期:2019-01-01 00:00:00

  • Undervaccination with diphtheria, tetanus, and pertussis vaccine: National trends and association with pertussis risk in young children.

    abstract:BACKGROUND:The high coverage for ≥3 pertussis vaccine doses among Taiwanese children might not imply timely vaccination. Recently, resurgence of pertussis and challenges with availability of DTaP-IPV-Hib prompted this study. METHODS:In the 1996-2012 national birth cohort, we calculated the prevalence and days of under...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2016.1249552

    authors: Huang WT,Lin HC,Yang CH

    更新日期:2017-04-03 00:00:00

  • No evidence of an increase in the incidence of norovirus gastroenteritis hospitalizations in young children after the introduction of universal rotavirus immunization in Israel.

    abstract::Following the introduction of universal immunization against rotavirus, concerns were raised regarding pathogen-replacement of rotavirus by norovirus. The study aim was to examine the incidence and characteristics and norovirus gastroenteritis before and after the introduction of universal rotavirus immunization in Is...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1599522

    authors: Muhsen K,Kassem E,Rubenstein U,Goren S,Ephros M,Shulman LM,Cohen D

    更新日期:2019-01-01 00:00:00

  • Immunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years: a randomized open-label study.

    abstract::The aim of this Phase IIIb, open-label, randomized study was to demonstrate the non-inferiority of immune responses and to assess the safety of a purified chick-embryo cell rabies vaccine (PCECV) in healthy Chinese children (6 to 17 years) and older adults (≥51 years) following 2 alternative intramuscular (IM) simulat...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.4161/21645515.2014.994460

    authors: Li R,Li Y,Wen S,Wen H,Nong Y,Mo Z,Xie F,Pellegrini M

    更新日期:2015-01-01 00:00:00

  • The use of technology to promote vaccination: A social ecological model based framework.

    abstract::Vaccinations are an important and effective cornerstone of preventive medical care. Growing technologic capabilities and use by both patients and providers present critical opportunities to leverage these tools to improve vaccination rates and public health. We propose the Social Ecological Model as a useful theoretic...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2018.1477458

    authors: Kolff CA,Scott VP,Stockwell MS

    更新日期:2018-07-03 00:00:00

  • Two-year antibody persistence in children vaccinated at 12-15 months with a measles-mumps-rubella virus vaccine without human serum albumin.

    abstract::One combined measles-mumps-rubella (MMR) vaccine without Human Serum Albumin (HSA) is currently licensed in the USA (M-M-R II; Merck, USA) and another has been developed (Priorix™ [MMR-RIT, GSK, Belgium]). In this follow-up study, children from USA or Puerto Rico, who had received one dose of M-M-R II or MMR-RIT at 12...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/21645515.2017.1309486

    authors: Berry AA,Abu-Elyazeed R,Diaz-Perez C,Mufson MA,Harrison CJ,Leonardi M,Twiggs JD,Peltier C,Grogg S,Carbayo A,Shapiro S,Povey M,Baccarini C,Innis BL,Henry O

    更新日期:2017-07-03 00:00:00

  • Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial.

    abstract::Human papillomavirus (HPV) vaccines are efficacious against HPV infections and associated lesions in women HPV-naïve at vaccination. However, vaccine efficacy (VE) against oncogenic, high-risk HPV (HR-HPV) types in women infected with any other HR-HPV type at first vaccination (baseline) remains unclear. This post-hoc...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1829411

    authors: Hu S,Xu X,Zhu F,Hong Y,Hu Y,Zhang X,Pan Q,Zhang W,Zhang C,Yang X,Yu J,Zhu J,Zhu Y,Chen F,Zhao S,Karkada N,Tang H,Bi D,Struyf F,Zhao F

    更新日期:2020-11-12 00:00:00

  • Current opinion and review on peanut oral immunotherapy.

    abstract::In the last decade, peanut oral immunotherapy research has shown promise as an alternative treatment to avoidance in peanut-allergic patients. Research has not only focused on desensitization, but also on immunologic changes and sustained-tolerance. This article reviews the current literature and the historical backgr...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.4161/hv.32190

    authors: Deol S,Bird JA

    更新日期:2014-01-01 00:00:00

  • A review of immunogenicity and tolerability of live attenuated Hepatitis A vaccine in children.

    abstract::Changing epidemiology of Hepatitis A virus (HAV) has led to an increased susceptibility of adolescents and adults to the infection. Vaccination can remarkably reduce the incidence and associated morbidity of HAV infection. This review is focused on the safety and efficacy of H2 strain derived live attenuated Hepatitis...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2016.1216286

    authors: Rao S,Mao JS,Motlekar S,Fangcheng Z,Kadhe G

    更新日期:2016-12-01 00:00:00